Anchor Capital Advisors LLC Lowers Stock Holdings in Johnson & Johnson $JNJ

Anchor Capital Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 153,520 shares of the company’s stock after selling 554 shares during the period. Anchor Capital Advisors LLC’s holdings in Johnson & Johnson were worth $23,450,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $65,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $186.23 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The firm has a fifty day moving average price of $183.83 and a 200-day moving average price of $168.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market cap of $448.68 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Bank of America lifted their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Argus set a $210.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.